JP2019533677A5 - - Google Patents

Download PDF

Info

Publication number
JP2019533677A5
JP2019533677A5 JP2019520598A JP2019520598A JP2019533677A5 JP 2019533677 A5 JP2019533677 A5 JP 2019533677A5 JP 2019520598 A JP2019520598 A JP 2019520598A JP 2019520598 A JP2019520598 A JP 2019520598A JP 2019533677 A5 JP2019533677 A5 JP 2019533677A5
Authority
JP
Japan
Prior art keywords
particle
particles
cancer
seq
liposome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019520598A
Other languages
English (en)
Japanese (ja)
Other versions
JP7127021B2 (ja
JP2019533677A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2017/050885 external-priority patent/WO2018071959A1/en
Publication of JP2019533677A publication Critical patent/JP2019533677A/ja
Publication of JP2019533677A5 publication Critical patent/JP2019533677A5/ja
Application granted granted Critical
Publication of JP7127021B2 publication Critical patent/JP7127021B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019520598A 2016-10-21 2017-08-18 細胞傷害性粒子 Active JP7127021B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016904292 2016-10-21
AU2016904292A AU2016904292A0 (en) 2016-10-21 Cytotoxic particles
PCT/AU2017/050885 WO2018071959A1 (en) 2016-10-21 2017-08-18 Cytotoxic particles

Publications (3)

Publication Number Publication Date
JP2019533677A JP2019533677A (ja) 2019-11-21
JP2019533677A5 true JP2019533677A5 (https=) 2020-07-16
JP7127021B2 JP7127021B2 (ja) 2022-08-29

Family

ID=62018376

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019520598A Active JP7127021B2 (ja) 2016-10-21 2017-08-18 細胞傷害性粒子

Country Status (8)

Country Link
US (2) US11260131B2 (https=)
EP (1) EP3528789A4 (https=)
JP (1) JP7127021B2 (https=)
CN (1) CN109862883A (https=)
AU (1) AU2017346936B2 (https=)
CA (1) CA3035835A1 (https=)
MX (1) MX2019004410A (https=)
WO (1) WO2018071959A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180037650A1 (en) * 2015-04-02 2018-02-08 Biosceptre (Uk) Limited Pain Treatment
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
CN114173811A (zh) * 2019-07-26 2022-03-11 生物权威(澳大利亚)有限责任公司 P2x7受体靶向治疗
US20240368282A1 (en) * 2021-09-01 2024-11-07 Biosceptre (Aust) Pty Ltd Methods and compositions for stimulating immune activity

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AUPQ968700A0 (en) 2000-08-28 2000-09-21 Intreat Pty Limited Treatment of urinary incontinence
US20040067196A1 (en) * 2000-10-11 2004-04-08 Brunke Karen J. Targeted therapeutic lipid constructs
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
CN100497386C (zh) 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
SE0301109D0 (sv) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
CN101484139A (zh) * 2006-05-15 2009-07-15 乔治敦大学 用于治疗剂或诊断剂的全身施用的抗体或抗体片段靶向的免疫脂质体的制备及其应用
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
ES2619681T3 (es) * 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CN101878229A (zh) * 2007-09-28 2010-11-03 巴塞尔大学医院 用于治疗癌症的免疫脂质体
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
CN101536982B (zh) * 2009-04-27 2011-11-09 中国人民解放军第二军医大学 Trastuzumab修饰的包裹毒素蛋白的PEG化免疫脂质体及其制备与应用
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) * 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
CN102429868A (zh) * 2011-12-09 2012-05-02 南开大学 具有肿瘤靶向、体内示踪和治疗作用的脂质体药物组合物及制备方法
US20180037650A1 (en) 2015-04-02 2018-02-08 Biosceptre (Uk) Limited Pain Treatment

Similar Documents

Publication Publication Date Title
JP2017500057A5 (https=)
JP7682789B2 (ja) Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用
JP2010535713A5 (https=)
JP2017532952A5 (https=)
JP2020525032A5 (https=)
JP2017535257A5 (https=)
JP2020501531A5 (https=)
JP2020502271A5 (https=)
JP2020516240A5 (https=)
JP2013527762A5 (https=)
HRP20231281T1 (hr) Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom
JP2009505676A5 (https=)
JP2021526509A5 (https=)
JP2018508483A5 (https=)
JP2009225799A5 (https=)
JP2019533677A5 (https=)
JP2014502955A5 (https=)
JP2017048240A5 (https=)
JP2014530215A5 (https=)
JP2017534254A5 (https=)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2015163068A5 (https=)
JP2015534577A5 (https=)
JP2014205674A5 (https=)
JP2013519364A5 (https=)